MAPT and Alzheimer disease: Of the candidate AD blood‐based biomarkers, phosphorylated tau (p‐tau)217 has emerged as most promising for clinical translation, showing high diagnostic accuracy rivaling that of PET and CSF biomarkers in its ability to detect AD pathology.22, 23, 24, 25